FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4224635314> ?p ?o ?g. }

• W4224635314 abstract "Background and Objectives To describe a new case of neuromyelitis optica spectrum disorder (NMOSD) induced by the administration of interferon-alpha (IFNα) and to raise awareness of this rare drug-induced disease of IFNα treatment. Methods A single case study and comprehensive literature review of eight cases. Results A 24-year-old man was diagnosed with cerebral venous thrombosis and essential thrombocythemia. He had been undergoing IFNα treatment (IFNα-2b, 3 million IU per day) without any side effects for 18 months, at which point the patient developed persistent hiccups, nausea, urinary retention, and numbness. Spinal magnetic resonance imaging revealed a longitudinal abnormality extending from the medulla to the entire spinal cord. The patient was positive for anti-aquaporin-4 antibody (AQP4-IgG) in both the serum and cerebrospinal fluid (CSF), which confirmed the diagnosis of NMOSD. Thus, recombinant IFNα-2b was suspended immediately. Because his condition did not improve after 6-day treatment of methylprednisolone pulse therapy (1,000 mg for 3 days, then 500 mg for 3 days), intravenous immunoglobulin (0.4 g/kg/day for 5 days) was administered. The patient gradually improved. Low-dose prednisolone and mycophenolate mofetil were subsequently administered as a long-term treatment. The patient was discharged with subtle limb numbness and their expanded disability status score (EDSS) was 1. At the 1-year follow-up, the patient had not relapsed and tested negative for AQP4-IgG. We further identified the eight patients with IFNα-induced NMOSD. The median onset age was 59 years, and the median time of IFNα exposure was 18 months. Optic neuritis was the most common initial symptom (five, 55.6%), followed by myelitis in three patients and area postrema syndrome in one patient. More than half (five, 55.6%) of the patients were monophasic. After IFNα discontinuation and immunotherapy, most (seven, 77.8%) patients remained relapse-free. However, only one patient was free of sequelae. Conclusion This study highlights the potential pathogenic risk of NMOSD of IFNα treatment. Given the high disability rates of this rare drug-induced disease, it is crucial to monitor the early manifestations of NMOSD during IFNα treatment." @default.
• W4224635314 created "2022-04-27" @default.
• W4224635314 creator A5002415002 @default.
• W4224635314 creator A5011525444 @default.
• W4224635314 creator A5038805449 @default.
• W4224635314 creator A5043112591 @default.
• W4224635314 creator A5062969598 @default.
• W4224635314 date "2022-04-25" @default.
• W4224635314 modified "2023-10-14" @default.
• W4224635314 title "Case Report: Interferon-Alpha-Induced Neuromyelitis Optica Spectrum Disorder" @default.
• W4224635314 cites W1916121669 @default.
• W4224635314 cites W1940795041 @default.
• W4224635314 cites W1984449814 @default.
• W4224635314 cites W1995913127 @default.
• W4224635314 cites W2012728808 @default.
• W4224635314 cites W2036172456 @default.
• W4224635314 cites W2036439151 @default.
• W4224635314 cites W2040213563 @default.
• W4224635314 cites W2043093344 @default.
• W4224635314 cites W2058420050 @default.
• W4224635314 cites W2059209526 @default.
• W4224635314 cites W2066718881 @default.
• W4224635314 cites W2074615338 @default.
• W4224635314 cites W2077641134 @default.
• W4224635314 cites W2082678538 @default.
• W4224635314 cites W2085416952 @default.
• W4224635314 cites W2097556922 @default.
• W4224635314 cites W2111516059 @default.
• W4224635314 cites W2128597204 @default.
• W4224635314 cites W2129229339 @default.
• W4224635314 cites W2161313322 @default.
• W4224635314 cites W2285374387 @default.
• W4224635314 cites W2286880442 @default.
• W4224635314 cites W2320543638 @default.
• W4224635314 cites W2338592803 @default.
• W4224635314 cites W2339096746 @default.
• W4224635314 cites W2339655433 @default.
• W4224635314 cites W2399001396 @default.
• W4224635314 cites W2611101771 @default.
• W4224635314 cites W2619143287 @default.
• W4224635314 cites W2884391850 @default.
• W4224635314 cites W2885090944 @default.
• W4224635314 cites W2888397273 @default.
• W4224635314 cites W2938304901 @default.
• W4224635314 cites W2945745581 @default.
• W4224635314 cites W2996665685 @default.
• W4224635314 cites W3033198321 @default.
• W4224635314 cites W3036134455 @default.
• W4224635314 cites W3036922302 @default.
• W4224635314 cites W3102350544 @default.
• W4224635314 cites W3109109640 @default.
• W4224635314 cites W3120898298 @default.
• W4224635314 cites W3186056785 @default.
• W4224635314 cites W3193418223 @default.
• W4224635314 cites W3205545191 @default.
• W4224635314 cites W3205898497 @default.
• W4224635314 cites W4205683421 @default.
• W4224635314 cites W4285719527 @default.
• W4224635314 cites W590477405 @default.
• W4224635314 doi "https://doi.org/10.3389/fneur.2022.872684" @default.
• W4224635314 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35547376" @default.
• W4224635314 hasPublicationYear "2022" @default.
• W4224635314 type Work @default.
• W4224635314 citedByCount "1" @default.
• W4224635314 countsByYear W42246353142022 @default.
• W4224635314 crossrefType "journal-article" @default.
• W4224635314 hasAuthorship W4224635314A5002415002 @default.
• W4224635314 hasAuthorship W4224635314A5011525444 @default.
• W4224635314 hasAuthorship W4224635314A5038805449 @default.
• W4224635314 hasAuthorship W4224635314A5043112591 @default.
• W4224635314 hasAuthorship W4224635314A5062969598 @default.
• W4224635314 hasBestOaLocation W42246353141 @default.
• W4224635314 hasConcept C126322002 @default.
• W4224635314 hasConcept C141071460 @default.
• W4224635314 hasConcept C203014093 @default.
• W4224635314 hasConcept C2776715498 @default.
• W4224635314 hasConcept C2777185649 @default.
• W4224635314 hasConcept C2780011451 @default.
• W4224635314 hasConcept C2780372218 @default.
• W4224635314 hasConcept C2780580376 @default.
• W4224635314 hasConcept C2780640218 @default.
• W4224635314 hasConcept C2780868729 @default.
• W4224635314 hasConcept C2781137167 @default.
• W4224635314 hasConcept C42219234 @default.
• W4224635314 hasConcept C71924100 @default.
• W4224635314 hasConcept C90924648 @default.
• W4224635314 hasConceptScore W4224635314C126322002 @default.
• W4224635314 hasConceptScore W4224635314C141071460 @default.
• W4224635314 hasConceptScore W4224635314C203014093 @default.
• W4224635314 hasConceptScore W4224635314C2776715498 @default.
• W4224635314 hasConceptScore W4224635314C2777185649 @default.
• W4224635314 hasConceptScore W4224635314C2780011451 @default.
• W4224635314 hasConceptScore W4224635314C2780372218 @default.
• W4224635314 hasConceptScore W4224635314C2780580376 @default.
• W4224635314 hasConceptScore W4224635314C2780640218 @default.
• W4224635314 hasConceptScore W4224635314C2780868729 @default.
• W4224635314 hasConceptScore W4224635314C2781137167 @default.
• W4224635314 hasConceptScore W4224635314C42219234 @default.
• W4224635314 hasConceptScore W4224635314C71924100 @default.
• W4224635314 hasConceptScore W4224635314C90924648 @default.

• next